Artificial cells for replacement of metabolic organ functions.
Artificial cells are being actively investigated for use in the replacement of cell and organ functions, especially related to metabolic functions. The earliest routine clinical use of artificial cells is in the form of coated activated charcoal for hemoperfusion. Implantation of encapsulated cells are being studied for the treatment of diabetes, liver failure, kidney failure and the use of encapsulated genetically engineered cells for gene therapy. Blood substitutes based on modified hemoglobin are already in Phase III clinical trials in patients with as much as 20 units infused into each patient during trauma surgery. Artificial cells containing enzymes are being developed for clinical trial in hereditary enzyme deficiency diseases and other diseases. Artificial cell is also being investigated for drug delivery and for other uses in biotechnology, chemical engineering and medicine.
Chang
Thomas Ming Swi
TM
Artificial Cells and Organs Research Centre, MSSS-FRSQ Research Group on Blood Substitutes in Transfusion Medicine, Physiology, Medicine, and Biomedical Engineering, Faculty of Medicine, McGill University, Montreal, Quebec, Canada. artcell.med@mcgill.ca
D001187:Artificial Organs; D001802:Blood Substitutes; D006801:Humans; D015918:Infusion Pumps, Implantable; D008661:Metabolism, Inborn Errors / Q000628:therapy; D023822:Tissue Engineering
D001802:Blood Substitutes